NeuroBo Pharmaceuticals Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 0
Bid Price 1.48
Ask Price 1.53
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
NeuroBo Pharmaceuticals Inc NRBO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.50 19:00:00
Open Price Low Price High Price Close Price Prev Close
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.50 USD


Draw Mode:

NeuroBo Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 39.89M 26.59M 10.71M $ - $ - -1.84 -0.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 676.67k 14.10%

more financials information »

NeuroBo Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NRBO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.511.561.311.44121,745-0.01-0.66%
1 Month1.771.851.311.65178,311-0.27-15.25%
3 Months3.814.28941.312.01575,663-2.31-60.63%
6 Months3.226.571.313.541,521,857-1.72-53.42%
1 Year5.727.60941.313.76894,199-4.22-73.78%
3 Years9.1530.001.314.01475,289-7.65-83.61%
5 Years9.1530.001.314.01475,289-7.65-83.61%

NeuroBo Pharmaceuticals Description

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.

Your Recent History
NeuroBo Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.